Journal of Clinical Anesthesia
Volume 21, Issue 6 , Pages 444-453 , September 2009

Sugammadex: the first selective binding reversal agent for neuromuscular block

Received 11 July 2008 ,Revised 28 April 2009 ,Accepted 19 May 2009.

References 

  1. Fuchs-Buder F, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789–808
  2. Claudius C, Viby-Morgensen J. Acceleromyography for use in scientific and clinical practice. Anesthesiology. 2008;108:1117–1140
  3. Hemmerling TM, Le N. Brief review: Neuromuscular monitoring: an update for the clinician. Can J Anaesth. 2007;54:58–72
  4. Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology. 1992;77:785–805
  5. Wachtel RE. Comparison of anticholinesterases and their effects on acetylcholine-activated ion channels. Anesthesiology. 1990;72:496–500
  6. Furguson A, Egerszegi P, Bevan DR. Neostigmine, pyridostigmine, and edrophonium as antagonists of pancuronium or vecuronium. Anesthesiology. 1986;64:711–714
  7. Donati F, McCarroll SM, Antzac C, et al. Dose-response curves for edrophonium, neostigmine and pyridostigmine after pancuronium and d-tubocurarine. Anesthesiology. 1987;66:471–475
  8. Morris RB, Cronnelly R, Miller RD, et al. Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. Anesthesiology. 1981;54:399–404
  9. Miller RD, Van Nyhuis LS, Eger , Vitez TS, Way WL. Comparative times to peak effect and durations of action of neostigmine and pyridostigmine. Anesthesiology. 1974;41:27–32
  10. Cronnelly R, Stanski DR, Miller RD, et al. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology. 1979;51:222–228
  11. Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042–1048
  12. Pavlin EG, Holle RH, Schoene RB. Recovery of airway protection compared with ventilation in humans after paralysis with curare. Anesthesiology. 1989;70:381–385
  13. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979;50:539–541
  14. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block. Br J Anaesth. 1971;43:478–485
  15. Fruergaard K, Viby-Mogensen J, Berg H, et al. Tactile evaluation of the response to double burst stimulation decreases, but does not eliminate, the problem of postoperative residual paralysis. Acta Anaesthesiol Scand. 1998;42:1168–1174
  16. Bevan DR, Smith CE, Donati F. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium, and pancuronium. Anesthesiology. 1988;69:272–276
  17. Hayes AH, Mirakhur RK, Breslin DS, et al. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia. 2001;56:312–318
  18. Baillard C, Gehan G, Reboul-Marty J, et al. Residual curarization in the recovery room after vecuronium. Br J Anaesth. 2000;84:394–395
  19. Murphy GS, Szokol JW, Franklin M, et al. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth Analg. 2004;98:193–200
  20. Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006;72:97–109
  21. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia. 2007;62:12–17
  22. Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology. 1997;87:1035–1043
  23. Eikermann M, Blobner M, Groeben H, et al. Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor policis muscle from neuromuscular blockade. Anesth Analg. 2006;102:937–942
  24. Eikermann M, Vogt FM, Herbstreit F, et al. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J Respir Crit Care Med. 2007;175:9–15
  25. Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology. 1993;78:693–699
  26. Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol Res. 2000;49:455–462
  27. Eikermann M, Fassbender P, Malhotra A, et al. Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesiology. 2007;107:621–629
  28. Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:103–107
  29. Drenck NE, Ueda N, Olsen NV, et al. Manual evaluation of residual curarization using double-burst stimulation: a comparison with train-of-four. Anesthesiology. 1981;54:594–597
  30. Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology. 1997;86:765–771
  31. Viby-Mogensen J, Jensen NH, Engbaek J, et al. Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology. 1985;63:440–443
  32. Eikermann M, Groeben H, Husing J, et al. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology. 2003;98:1333–1337
  33. Saddler JM, Bevan JC, Donati F, et al. Comparison of double-burst and train-of-four stimulation to assess neuromuscular block in children. Anesthesiology. 1990;73:401–403
  34. Capron F, Alla F, Hottier C, et al. Can acceleromyuography detect low levels of residual paralysis?. Anesthesiology. 2004;100:1119–1124
  35. Magorian T, Lynam DP, Caldwel JE, et al. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade. Anesthesiology. 1990;73:410–414
  36. Sikharam S, Egan TD, Kern SE. Cyclodextrins as new formulation entities and therapeutic agents. Curr Opin Anaesthesiol. 2005;18:392–395
  37. Challa R, Ahuja A, Ali J, Khar R. Cyclodestrins in drug delivery: an updated review. AAPS PharmSciTech. 2005;06:E329–E357http://www.aapspharmscitech.org/view.asp?art=pt060243. Accessed April 28, 2009
  38. Tarver GJ, Grove SJ, Buchanan K, et al. 2-0-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chern. 2002;10:1819–1827
  39. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Agnew Chem Int Ed Engl. 2002;41:276–280
  40. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104:575–581
  41. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695–703
  42. Nicholson WT, Sprung J, Jankowski C. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy. 2007;27:1181–1188
  43. Miller S, Bom A. Org 25969 causes selective reversal of neuromuscular blockade induced by steroidal NMBs in the mouse hemi-diaphragm preparation. Eur J Anaesthesiol. 2001;18(Suppl 23):100–101
  44. de Boer HD, van Egmond J, van de Pol F, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth. 2006;96:473–479
  45. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003;99:632–637
  46. de Boer H, Driessen JJ, Marcus MAE, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex—a multicenter, dose-finding and safety study. Anesthesiology. 2007;107:239–244
  47. Suy K, Morias K, Hans P, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106:283–288
  48. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant bidding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006;96:36–43
  49. Rex C, Khuenl-Brady K, Sielenkaemper A, Kjaer CC, Pueringer FK. Reversal of high-dose rocuronium (1.2 mg/kg) with Org 25969. [Abstract] Anesthesiology. 2005;103:A1129
  50. Puhringer F, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. An international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109:188–197
  51. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569–574
  52. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104:667–674
  53. Vanacker BF, Vermeyen KM, Struys MM, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg. 2007;104:563–568
  54. Kim KS, Cheong MA, Lee HJ, et al. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg. 2004;99:1080–1085
  55. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex. A randomized comparison with neostigmine. Anesthesiology. 2008;109:816–824
  56. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106:935–943
  57. Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104:555–562
  58. Elevald DJ, Kkuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg. 2007;104:582–584
  59. Dahl V, Pendeville PE, Hollman MW, Heier T, Blobner M. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. [Abstract] Anesthesiology. 2007;107:A1581
  60. Amao R, Zornow MH, Cowan RM, Cheng DC, Allard M. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. [Abstract] Anesthesiology. 2007;107:A1582
  61. McDonagh DL, Benedict PE, Kovac AL, Drover D, Brister NW. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. [Abstract] Anesthesiology. 2007;107:A1583
  62. Lenz A, Hill G, White PF. Emergency use of sugammadex after failure of standard reversal drugs. Anesth Analg. 2007;104:585–586
  63. de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/Qtc prolongation. [Abstract] Anesthesiology. 2007;107:A1580
  64. Meeting of the Anesthetic and Life Support Drugs FDA Advisory Committee, March 11, 2008; Silver Springs, MD. Sugammadex NDA 22-225. Presentations by Schering-Plough and the FDA. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4346s1-01-Schering-Plough-corebackup.pdf. Accessed September 9, 2009.
  65. Burkett L, Bikhazi GB, Thomas KC, Kjaer CC, Puehringer FK. Mutual potentiation of the neuromuscular effects of antibiotics and relaxants. Anesth Analg. 1979;58:107–115
  66. Miller RD. Sugammadex: an opportunity to change the practice of anesthesiology?. Anesth Analg. 2007;104:477–478
  67. Sugammadex EU prescribing information. http://www.bridion.com/HCP/about_bridion/dosage_and_administration/index.asp?searchword=EU%20precribing%20informationAccessed September 9, 2009

☆ There were no sources of funding for the preparation of this manuscript.

☆☆ Dr. Kovac has received grant support from Organon (now Schering-Plough) and participated on the Speakers Bureau for Organon.

PII: S0952-8180(09)00218-9

doi: 10.1016/j.jclinane.2009.05.002

Journal of Clinical Anesthesia
Volume 21, Issue 6 , Pages 444-453 , September 2009

Article Tools